Cancer Letters
Volume 294, Issue 1 , Pages 66-73 , 1 August 2010

Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity

  • Ming Lv

      Affiliations

    • Institute of Basic Medical Sciences, Beijing, 100850, China
    • These authors contributed equally to this work.
    • ,
  • Zhou Lin

      Affiliations

    • Institute of Basic Medical Sciences, Beijing, 100850, China
    • These authors contributed equally to this work.
    • ,
  • Chunxia Qiao

      Affiliations

    • Institute of Basic Medical Sciences, Beijing, 100850, China
    • ,
  • Shusheng Gen

      Affiliations

    • Beijing Tian Guang Shi Biotech Co. Ltd., Beijing, 100176, China
    • ,
  • Xiaoling Lang

      Affiliations

    • Beijing Tian Guang Shi Biotech Co. Ltd., Beijing, 100176, China
    • ,
  • Yan Li

      Affiliations

    • Institute of Basic Medical Sciences, Beijing, 100850, China
    • ,
  • Jiannan Feng

      Affiliations

    • Institute of Basic Medical Sciences, Beijing, 100850, China
    • ,
  • Beifen Shen

      Affiliations

    • Institute of Basic Medical Sciences, Beijing, 100850, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 10 66931325; fax: +86 10 68159436.

Received 17 December 2009 ,Revised 20 January 2010 ,Accepted 20 January 2010.

References 

  1. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15:450–454
  2. Maloney DG. Immunotherapy for non-Hodgkin’s lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005;23:6421–6428
  3. Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, et al. Semin Hematol. 2008;45(2):126–132Apr
  4. Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today. 2003;8:503–510
  5. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 1998;10:548–551
  6. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006;56:226–243
  7. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  8. Maloney DG, Grillo-Lo´pez AJ, Bodkin DJ, et al. IDECC2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15:3266–3274
  9. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol Suppl. 2007;67(Jan):5–14
  10. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20(4):444–449Aug
  11. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanism of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823–3837
  12. Golay J, Gramigna R, Facchinetti V, Capello D, Introna M. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol. 2002;119:923–929
  13. Natsume A, Shimizu-Yokoyama Y, Satoh M, Shitara K, Niwa R.Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Cancer Sci. 2009 Aug 25. [Epub ahead of print].
  14. Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, et al. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol. 2007;31(1):29–40Jul
  15. Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008;68(7):2400–2408Apr 1
  16. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Wang Y, Chang CH. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68(20):8384–8392Oct 15
  17. Huang Y, Li Y, Wang YG, Gu X, Wang Y, Shen BF. An efficient and targeted gene integration system for high-level antibody expression. J Immunol Methods. 2007;322(1-2):28–39Apr 30
  18. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443–446
  19. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171:1581–1587
  20. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172:3280–3288
  21. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood. 2002;99:754–758
  22. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–3947
  23. Therapy with immunoglobulin: applications for monoclonal antibodies Stowell CP. J Infus Nurs. 2006;29(3 Suppl):S29–44May-Jun
  24. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia Plosker GL, Figgitt DP. Drugs. 2003;63(8):803–843
  25. Immunologic monitoring during OKT 3 therapy Chatenoud L. Clin Transplant. 1993;7(4 Pt 2):422–430Aug

PII: S0304-3835(10)00049-2

doi: 10.1016/j.canlet.2010.01.023

Cancer Letters
Volume 294, Issue 1 , Pages 66-73 , 1 August 2010

Article Tools

* Image Usage & Resolution